Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Radiation Oncology Quality of Life Abnd Tissue Banking Protocol

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2013 by Abramson Cancer Center of the University of Pennsylvania
Sponsor:
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01577251
First received: April 12, 2012
Last updated: February 25, 2013
Last verified: February 2013
  Purpose

The goal of this study is two-fold: to establish a tissue banking respository (defined as blood, urine, soft tissue, tumor specimen, and normal tissue from areas surrounding tumor specimens), and to prospectively assess health related quality of life (QOL) over time in patients with a pathologically confirmed diagnosis of neoplasia receiving radiotherapy or photodynamic therapy (PDT)


Condition
Patients With Pathologically Confirmed Neoplasia That Have Been
Selected for Definitive Photodynamic Therapy, Proton, or Photon
Radiotherapy.

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Radiation Oncology Quality of Life and Tissue Banking Protocol

Resource links provided by NLM:


Further study details as provided by Abramson Cancer Center of the University of Pennsylvania:

Primary Outcome Measures:
  • Health Assessments [ Designated as safety issue: No ]

Study Start Date: June 2008
  Eligibility

Ages Eligible for Study:   up to 89 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Donors will be between the ages of 18 and 89 with pathologically confirmed neoplasia that are selected for definitive photodynamic therapy, proton, photon radiotherapy

-Pediatric patients with pathologically confirmed neoplasia that have been selected for definitive radiotherapy may elect to participate in a pediatric arm of quality of life, provided that the proper processes of parental permission and assent have occurred.

Criteria

Inclusion Criteria:

  • Donors will be between the ages of 18 and 89 with pathologically confirmed neoplasia that are selected for definitive photodynamic therapy, proton, photon radiotherapy
  • Pediatric patients with pathologically confirmed neoplasia that have been selected for definitive radiotherapy may elect to participate in a pediatric arm of quality of life, provided that the proper processes of parental permission and assent have occurred.
  • Patients between the ages of 18 and 89 receiving palliative proton or photon radiotherapy will be eligible to permit the collection of their clinical and technical data for the purpose of the IGRT Registry component of this protocol.

Exclusion Criteria:

  • Patient under the age of 18 will not be eligible to participate in the tissue banking component of this study.
  • Patient presenting for palliative proton or photon radiotherapy will be excluded from the QOL and Tissue Banking components of this study.
  • Patients over the age of 89 will excluded from all arms of this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01577251

Contacts
Contact: Ramesh Rengan, MD 855-216-0098 PennCancerTrials@emergingmed.com

Locations
United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19004
Contact: Ramesh Rengan, MD    855-216-0098    PennCancerTrials@emergingmed.com   
Principal Investigator: Ramesh Rengan, MD         
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
Investigators
Principal Investigator: Ramesh Rengan, MD Abramson Cancer Center of the University of Pennsylvania
  More Information

No publications provided

Responsible Party: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier: NCT01577251     History of Changes
Other Study ID Numbers: UPCC 11908
Study First Received: April 12, 2012
Last Updated: February 25, 2013
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on November 20, 2014